Cellectis to Release Financial Results for 2024
NEW YORK -- Cellectis (NASDAQ: CLLS), a progressive biotechnology firm dedicated to developing innovative cell and gene therapies, is preparing to unveil its financial results for the fourth quarter and full year of 2024. This anticipated release will occur following the closure of the U.S. market on March 13, 2025.
Investor Conference Call Scheduled
Following the financial report, Cellectis will conduct an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET. This call aims to provide investors with insights into the company’s performance and business updates for the given year.
Details for the Upcoming Call
Interested parties can join the call using the following dial-in information:
- Domestic: +1-800-225-9448
- International: +1-203-518-9708
- Conference ID: CLLS24
For those preferring to attend via online streaming, the webcast will be available here.
About Cellectis and Its Innovative Approaches
Cellectis is committed to revolutionizing gene therapies using its cutting-edge gene-editing platform. The organization focuses on an allogeneic approach for CAR T-cell immunotherapies, enabling off-the-shelf products that can be quickly utilized to treat cancer patients.
With robust in-house manufacturing capabilities, Cellectis stands out as one of the few fully integrated gene editing companies, managing the entire production process of cell and gene therapies from conception to clinic. This vertical integration enhances their ability to deliver timely and effective solutions in the fight against cancer.
Global Reach of Cellectis
Headquartered in Paris, France, with additional operations in New York and Raleigh, Cellectis operates on a global scale. The company is publicly traded on the NASDAQ Global Market under the ticker symbol CLLS and also listed on Euronext Growth as ALCLS. This financial visibility supports Cellectis' efforts in funding its innovative research and development endeavors.
Contacting Cellectis
For those seeking further information about Cellectis and its groundbreaking work in biotechnology, please reach out to:
Media Inquiries
Pascalyne Wilson
Director of Communications
Phone: +33 (0)7 76 99 14 33
Email: media@cellectis.com
Investor Relations
Arthur Stril
Chief Financial Officer & Chief Business Officer
Email: investors@cellectis.com
Frequently Asked Questions
When will Cellectis announce its financial results?
Cellectis will announce its financial results for Q4 and full year 2024 on March 13, 2025.
How can I participate in the investor conference call?
You can join the investor conference call on March 14, 2025, using the provided dial-in information or via the webcast link.
What markets does Cellectis operate in?
Cellectis operates globally, with major operations in Paris, New York, and Raleigh, and is involved in the biotechnology sector focusing on gene therapies.
How can I contact Cellectis for media inquiries?
You can contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or via email at media@cellectis.com.
What are the future plans for Cellectis?
Cellectis aims to further enhance its gene editing platform while expanding its pipeline of innovative therapies to meet pressing medical needs.